Paul Hudson, via Getty Images (Bloomberg)

Sanofi walks back Paul Hud­son’s promise of ear­ly vac­cine ac­cess for the US, French min­is­ters call it 'u­nac­cept­able'

Sanofi CEO Paul Hud­son’s com­ments yes­ter­day that the US will get first ac­cess to the com­pa­ny’s Covid-19 vac­cine, should it be ap­proved, were met with swift back­lash yes­ter­day in France, both from his own com­pa­ny and a mem­ber of the French gov­ern­ment.

First, hours af­ter Hud­son’s in­ter­view ap­peared on Bloomberg.com, Sanofi emailed jour­nal­ists a terse state­ments walk­ing back its CEO’s re­marks– sort of. The com­pa­ny said that while vac­cines from US pro­duc­tion will be main­ly pre­served for Amer­i­cans, pro­duc­tion ca­pac­i­ty else­where will sup­ply Eu­rope and the rest of the globe. The tech­nol­o­gy Sanofi us­es for its Covid-19 vac­cine can­di­date is pri­mar­i­ly man­u­fac­tured in the US, al­though the com­pa­ny said it is ex­pand­ing ca­pac­i­ty in ex­ist­ing fa­cil­i­ties in Eu­rope and else­where.

“We have al­ways been com­mit­ted in these un­prece­dent­ed cir­cum­stances to make our vac­cine ac­ces­si­ble to every­one,” they wrote. “Sanofi ben­e­fits from a di­ver­si­fied foot­print around the world. We have man­u­fac­tur­ing ca­pac­i­ty in the US, Eu­rope and all oth­er main re­gions. The US pro­duc­tion will be main­ly for the US and the rest of the man­u­fac­tur­ing ca­pac­i­ty will cov­er Eu­rope and the rest of the world.”

Then a French of­fi­cial ap­peared on a ra­dio show and called any plan to give Amer­i­cans first ac­cess “un­ac­cept­able.”

”For us, it would be un­ac­cept­able that there be priv­i­leged ac­cess for this or that coun­try on a pre­text that would be a fi­nan­cial pre­text,” ju­nior econ­o­my min­is­ter, Agnes Pan­nier-Runach­er, said on an in­ter­view with Sud Ra­dio.

Hud­son told Bloomberg on Wednes­day that “The U.S. gov­ern­ment has the right to the largest pre-or­der” of the ex­per­i­men­tal vac­cine be­cause a US agency, BAR­DA, has fund­ed its de­vel­op­ment. “It’s in­vest­ed in tak­ing the risk,” Hud­son said.

Hud­son’s com­ments en­tered in­to a sim­mer­ing bat­tle over who will get a vac­cine once it’s ap­proved. That bat­tle has par­tic­u­lar­ly cen­tered on the US and the Trump ad­min­is­tra­tion, which has poured over $1 bil­lion in­to top com­pa­nies de­vel­op­ing vac­cines but has es­chewed in­ter­na­tion­al co­op­er­a­tion — in­clud­ing an $8 bil­lion fund raised ear­li­er this month — in fa­vor of an in­ter­nal and thus far vague­ly de­fined ef­fort to get Amer­i­cans in­oc­u­lat­ed first.

The de­bate be­gan in earnest in March, when Reuters and a lead­ing Ger­man news­pa­per re­port­ed that the Trump ad­min­is­tra­tion tried to lure Ger­man mR­NA vac­cine com­pa­ny Cure­Vac to the Unit­ed States. Al­though Cure­Vac de­nied the re­ports, Ger­man sci­en­tists and of­fi­cials re­spond­ed with dis­may and ac­ri­mo­ny, con­demn­ing ef­forts for any coun­try to se­cure ex­clu­sive ac­cess to a vac­cine. The EU sub­se­quent­ly gave Cure­Vac an $89 mil­lion grant, in part to ex­pand man­u­fac­tur­ing on the con­ti­nent.

Since then, As­traZeneca has al­so promised some ear­ly ac­cess to the UK for the vac­cine its build­ing out of Ox­ford, while some world lead­ers have called for more uni­ver­sal ac­cess. To­day, UN­AIDS and OX­FAM re­leased a let­ter call­ing for a “Peo­ple’s Vac­cine” by which the WHO “es­tab­lish­es a glob­al and eq­ui­table rapid man­u­fac­tur­ing and dis­tri­b­u­tion plan – that is ful­ly-fund­ed by rich na­tions – for the vac­cine and all COVID-19 prod­ucts and tech­nolo­gies that guar­an­tees trans­par­ent ‘at true cost-prices.”

The lead­ing vac­cine man­u­fac­tur­ers are tak­ing ef­forts to dra­mat­i­cal­ly ex­pand ca­pac­i­ty, but ex­perts warn that any vac­cines will come in batch­es, rather than all at once.

BAR­DA, found­ed in 2005 to pro­tect the US from bi­o­log­ic threats, is fund­ing some of the world’s lead­ing Covid-19 vac­cine ef­forts, back­ing not on­ly Sanofi, but al­so putting around $1 bil­lion be­hind J&J and Mod­er­na’s ef­forts. Over the last 15 years, they have fund­ed both Sanofi and its re­com­bi­nant vac­cine sub­sidiary Pro­tein Sci­ences, which is mak­ing the Covid-19 vac­cine, to shore up ca­pac­i­ty to build a pan­dem­ic vac­cine. This spring, they in­vest­ed around $30 mil­lion be­hind the Pro­tein Sci­ences ef­fort.

Pro­tein Sci­ences’ re­com­bi­nant vac­cines are pri­mar­i­ly made at a BAR­DA-fund­ed fa­cil­i­ty in Pearl Riv­er, New York. The com­pa­ny’s BAR­DA-fund­ed man­u­fac­tur­ing fa­cil­i­ty in Swift­wa­ter, Penn­syl­va­nia will al­so be used. There is an ad­di­tion­al part­ner­ship with Uni­gen in Japan.

In his re­marks, Hud­son was crit­i­cal of Eu­rope for fail­ing to back pri­vate vac­cine ef­forts, call­ing the US and Chi­na a “mod­el” of pri­vate-pub­lic part­ner­ship and warn­ing, “don’t let Eu­rope be left be­hind.” The French phar­ma gi­ant said they are work­ing on ex­pe­dit­ing the process of get­ting vac­cines to Eu­rope.

“The co­op­er­a­tion we have with BAR­DA in the US al­lows us to ini­ti­ate pro­duc­tion as ear­ly as pos­si­ble while we con­tin­ue to de­vel­op and reg­is­ter the vac­cine,” Sanofi said. “In the mean­time, we are very en­cour­aged to see the mo­bi­liza­tion of the EU Com­mis­sion over the past weeks, ex­plor­ing sim­i­lar mea­sures that could ex­pe­dite both vac­cines de­vel­op­ment and ac­cess to the Eu­ro­pean pop­u­la­tion. We are hav­ing very con­struc­tive con­ver­sa­tions with the EU in­sti­tu­tions and the French and Ger­man gov­ern­ment amongst oth­ers.”

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

Janet Woodcock (AP Images)

Janet Wood­cock to be act­ing FDA com­mis­sion­er while Biden team fi­nal­izes nom­i­nee — re­ports

Janet Woodcock is set to be the most powerful person at the FDA in less than a week.

The veteran regulator and longtime director of the Center for Drug Evaluation and Research has been tapped as acting commissioner of the FDA, according to reports by BioCentury’s Steve Usdin and Pink Sheet’s Sarah Karlin-Smith.

The appointment was requested by the incoming Biden team, Karlin-Smith added, as they sort out the nomination of a permanent successor to Stephen Hahn — whose one-year tenure has been defined by Covid-19.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.

Janet Woodcock (AP Images)

Janet Wood­cock is in the run­ning for FDA com­mis­sion­er — what does that mean for the agen­cy's fu­ture?

Just a day after reports emerged that Janet Woodcock will serve as interim chief of the FDA, word has gotten out that she is also in the running for the permanent job.

The decision, as the initial wave of reactions suggest, could have dramatic implications for where the agency is headed in the next four years — if not beyond.

Woodcock, the longtime CDER director, is being vetted alongside former FDA principal deputy commissioner Joshua Sharfstein, Bloomberg reported. Already tapped as acting head of the agency, she’s set to take over from Stephen Hahn right after Biden’s inauguration next week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.

CEO Brett Monia (Ionis)

Can Brett Mo­nia push Io­n­is be­yond Spin­raza?

For 30 years, Brett Monia struggled as one of Ionis’ top scientists to get their antisense technology to work. Now, as CEO, he’s trying to use it to turn Ionis into one of the industry’s biggest biotechs.

Monia, one of the handful of young scientists who in 1989 followed Stanley Crooke across the country from SmithKline (now GSK) in Philadelphia to found Ionis in Northern California, replaced Crooke as CEO last January. By then, they had proven antisense, an RNA-based method for manipulating gene expression, could work dramatically well in at least some instances, transforming spinal muscular atrophy with the Biogen-partnered blockbuster Spinraza.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.

David Kessler in April 2009 (Eric Risberg/AP Images)

Covid-19 roundup: Hack­ers start re­leas­ing 'ma­nip­u­lat­ed' Covid-19 vac­cine docs; Ex-FDA com­mish David Kessler to re­place Mon­cef Slaoui as Op­er­a­tion Warp Speed chief — re­port

There’s a new twist on the EMA Covid-19 hacking story.

Friday the European agency put out the 5th in a series of statements about the hackers who broke into their system, noting that some of the information on vaccines that was gleaned in the attack is showing up online — altered to raise questions about the Covid-19 vaccines now in use.

This included internal/confidential email correspondence dating from November, relating to evaluation processes for COVID-19 vaccines. Some of the correspondence has been manipulated by the perpetrators prior to publication in a way which could undermine trust in vaccines.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.

Steve Harr (L) and Hans Bishop

Paint­ing by the num­bers, Sana founders carve up a gi­ant uni­corn-sized IPO — for a biotech that has­n't quite made it to the clin­ic

Sana Biotechnology is one of those startups that was sketched in on the chalkboard day one in the shape of a unicorn.

A giant unicorn.

And from the numbers the cell therapy 2.0 play spelled out in their S-1 $SANA, it’s clear that the company founders — led by a pair of major VCs aligned with some high-profile industry figures — are hunting a big chunk of that value for themselves.

The raise they penciled in — $150 million — isn’t likely what they actually have in mind, and it doesn’t do justice to the size of their ambitions.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Terry Rosen, Arcus CEO

Gilead part­ner Ar­cus earns an­a­lyst­s' plau­dits for ear­ly pan­cre­at­ic can­cer da­ta that 'ex­ceed­ed ex­pec­ta­tion­s'

Arcus’ small molecule CD73 inhibitor for pancreatic cancer got a standing ovation from analysts who said preliminary data “exceeded expectations”— making waves in a field that’s seen little progress in several years and proving the candidate could be worth the hundreds of millions Gilead provided upfront in a deal that included more than a billion dollars for opt-in rights and milestones.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.

Paul Stoffels, J&J CSO (Andrew Harnik/AP Images)

J&J on track to roll out sin­gle-shot Covid-19 vac­cine in March, Paul Stof­fels con­firms, al­though man­u­fac­tur­ing de­lays raise ques­tions

We should know how effective J&J’s Covid-19 vaccine — the single shot that’s closest to potential authorization — is by the end of this month or early February.

CSO Paul Stoffels added that they are on track to roll out the vaccine in March, just as the pharma giant published Phase I/IIa results in the New England Journal of Medicine. But a New York Times report also raises doubts about how many it can actually deliver in spring, citing unanticipated manufacturing delays.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.

With KRAS break­through on the hori­zon, Am­gen's David Reese re­flects on so­tora­si­b's loom­ing re­view date and murky fu­ture

After decades of failures laid waste to R&D outfits looking to solve the KRAS G12C puzzle, Amgen is as close as anyone ever has been to an approval with sotorasib. For Amgen R&D head David Reese, the drug’s looming review date is a point of reflection for his own career and a big milestone for Amgen’s blooming — if controversial — next-gen oncology pipeline.

Amgen filed its FDA application for sotorasib in December to treat metastatic non-small cell lung cancer with the KRAS mutation — once thought to be “undruggable” — months after the agency offered its breakthrough designation based on pivotal Phase I data showing previously unheard of response rates.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,000+ biopharma pros reading Endpoints daily — and it's free.

News brief­ing: Five Prime fi­nal­izes PhI­II plans for gas­tric can­cer; AI di­ag­nos­tics-fo­cused Paige ex­pands staff

Five Prime Therapeutics has finalized a plan to take their comeback gastric cancer drug into late-stage studies.

The South San Francisco-based biotech released full Phase II data for bemarituzumab on Friday, which Five Prime said in November met all of its pre-specified efficacy endpoints in a topline readout. Now, the company is announcing it plans to launch a Phase III trial for the program in 2021. Following November’s readout, the future of bemarituzumab had not yet been finalized.